QuidelOrtho (QuidelOrtho) ROCE % : 1.92% (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is QuidelOrtho ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. QuidelOrtho's annualized ROCE % for the quarter that ended in Dec. 2023 was 1.92%.

QuidelOrtho ROCE % Historical Data

The historical data trend for QuidelOrtho's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QuidelOrtho ROCE % Chart

QuidelOrtho Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

12.85

90.54

49.47

16.28

1.92

QuidelOrtho Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															4.01	5.16	-1.01	1.61	1.92

QuidelOrtho ROCE % Calculation

QuidelOrtho's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	149.8	/	( ( (8855.8 - 1007)	+	(8563.1 - 833.8) )	/ 2 )
	=	149.8	/	( (7848.8	+	7729.3)	/ 2 )
	=	149.8	/	7789.05
	=	1.92 %

QuidelOrtho's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	148	/	( ( (8539.1 - 860)	+	(8563.1 - 833.8) )	/ 2 )
	=	148	/	( ( 7679.1	+	7729.3 )	/ 2 )
	=	148	/	7704.2
	=	1.92 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

QuidelOrtho (NAS:QDEL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

QuidelOrtho ROCE % Related Terms

Thank you for viewing the detailed overview of QuidelOrtho's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

QuidelOrtho (QuidelOrtho) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » QuidelOrtho Corp (NAS:QDEL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

QL1A:Germany

Address

9975 Summers Ridge Road, San Diego, CA, USA, 92121

Website

https://www.quidelortho.com

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make better decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.

Executives

Louise Brandy	officer: SVP, Chief Information Officer	9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Patrick Klein	officer: Chief Administrative Officer	9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Christopher M Smith	director	125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Edward L. Michael	director	618 SHERIDAN SQUARE, EVANSTON IL 60202
William J. Ferenczy	officer: SVP, Cardio/Metabolic Unit	9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Werner Kroll	officer: SVP, Research and Development	12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Kenneth F Buechler	director
Robert R. Schmidt	director	C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Tamara A. Ranalli	officer: SVP, Molecular Bus. Unit	9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Stephen H. Wise	director	C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Robert Joseph Bujarski	officer: See Remarks	C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Wilkins Joseph D Jr.	director	82414 PUCCINI DRIVE, INDIO CA 92203
Michelle A. Hodges	officer: SVP, General Counsel	9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Douglas C Bryant	director, officer: Chairman & CEO	C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Joseph M Busky	officer: Chief Financial Officer	1717 DEERFIELD ROAD, DEERFIELD IL 60015